News
Halozyme Therapeutics (NASDAQ:HALO) reported non-GAAP earnings per share (EPS) of $1.54, beating non-GAAP estimates by $0.30 and growing 69% year over year (non-GAAP). Revenue (GAAP) was $325.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback